policy+practice

You'd think any drug developed to help fight the pandemic would be affordable, right? Nope. Here's how Gilead plans to make billions in profits off human suffering.

By requiring hospitals to post real prices and insurers to disclose reimbursement rates, Congress can help patients and stimulate the economy.

In a 7-2 ruling in a case involving the Little Sisters of the Poor, the court said employers with a “religious or moral objection” to contraceptives should not be forced to insure women for those services.

The deals cover Roche’s arthritis drug RoActemra and Merck’s multiple sclerosis drug Rebif - both seen as potential COVID-19 therapies - and will secure supplies for any of the 27 European Union member states wanting to buy them.

The United States reported more than 60,000 new Covid-19 cases on Tuesday, setting a fresh record for new cases reported in a single day, according to data compiled by Johns Hopkins University.

For years, the pharmaceutical industry has faced withering bipartisan criticism and a deteriorating reputation among the public for its role in driving up drug prices.

It does appear that the Minnesota Legislature is going to have to come up with a new plan for providing insulin to people who can’t afford it.

A pandemic hasn’t stopped some pharma companies from implementing their traditional mid-year price hikes.

The Drug Controller General of India has asked the state drug regulators and the National Pharma Pricing Authority to enforce the maximum retail price of the experimental Covid-19 drug Remdesivir.

The U.S. government has signed a $450 million contract with Regeneron Pharmaceuticals Inc for its potential COVID-19 antibody cocktail.

The U.S. has formally notified the World Health Organization it will withdraw from the United Nations agency. The exit won’t take effect until next July; Biden says U.S. would remain in WHO if he’s elected.

A Dutch government commission on compulsory licensing was nearly sabotaged last month after one of its members leaked information to a pharmaceutical industry trade group.

The U.S. government has provided Regeneron with $450 million contract to supply and manufacture its Covid-19 anti-viral antibody cocktail.

Gilead’s goal is to work with health authorities to ensure rapid and broad access to remdesivir to help ease the significant burden that COVID-19 has brought to the world.

Pharmaceutical companies in the United States have logged more than 800 price increases this year.